Explore the latest in PCI, including evolving indications, technologies, and use of antiplatelet agents to maximize efficacy and safety.
This cohort study assesses the association of reporting high-sensitivity cardiac troponin T level to the lowest limit of quantification vs conventional reporting with clinical outcomes and resource use.
This systematic review and network meta-analysis investigates the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention with drug-eluting stents.
This cross-sectional study assesses the generalizability of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) guideline by examining the representation of older adults in studies cited in the guideline.
This prespecified analysis of the POST-PCI randomized clinical trial analyzes clinical outcomes in patients with vs without acute coronary syndrome (ACS) who have undergone high-risk percutaneous coronary intervention (PCI) according to a follow-up strategy of routine surveillance stress testing vs standard care.
This secondary analysis of a randomized clinical trial examines the occurrence of target vessel failure and the role of diabetes in the clinical outcomes of patients undergoing complex percutaneous coronary intervention.
This cohort study evaluates the association of angiographic findings and post鈥損ercutaneous coronary intervention (PCI) physiologic parameters according to residual functional disease burden among patients undergoing second-generation drug-eluting stent implantation.
This systematic review and meta-analysis investigates clinical outcomes and postdischarge treatment after acute coronary syndromes or revascularization among people living with HIV.
This cohort study examines the risk of ventricular tachycardia or ventricular fibrillation 1 or more days after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI).
This randomized clinical trial evaluates clopidogrel monotherapy vs dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions who are at high bleeding and ischemic risk.
This study examines whether payments from a left ventricular assist device manufacturer to cardiologists performing percutaneous coronary intervention were associated with any use of the devices.
This prespecified subanalysis of the RENOVATE-COMPLEX-PCI trial evaluates potential differences in outcomes with intravascular imaging鈥揼uided percutaneous coronary intervention of complex coronary artery lesions between women and men.
This randomized clinical trial assesses the effect of culprit lesion percutaneous coronary intervention before coronary angiography vs coronary angiography followed by culprit lesion percutaneous coronary intervention on reperfusion times for patients with ST-elevation myocardial infarction.
This systematic review and network meta-analysis investigates the risk of adverse clinical events associated with different durations of dual antiplatelet therapy for older adults after percutaneous coronary intervention.
This systematic review and individual patient data meta-analysis assesses the risks and benefits of ticagrelor monotherapy or clopidogrel monotherapy compared with standard dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).
This cohort study assesses in-hospital mortality among adults at US rural and urban hospitals during vs before the COVID-19 pandemic for non鈥揅OVID-19 time-sensitive conditions.
Customize your 糖心vlog experience by selecting one or more topics from the list below.